Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT03213587
Phase
PHASE2
Status
Unknown

Conditions

  • Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Study Details

To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy

Key Dates

Start date
Jul 1, 2017
Status verified
Jul 2017
Primary completion
Jul 31, 2020
Completion
Jul 31, 2020

Study Design

Enrollment
51 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib

Primary Outcome Measure

CBR(Clinical Benefit Rate) [ Time Frame: 12 weeks ]

Related Studies